| Molecular Formula | C24H29N5O3 |
| Molar Mass | 435.52 |
| Density | 1.212±0.06 g/cm3(Predicted) |
| Melting Point | 116-117°C |
| Boling Point | 684.9±65.0 °C(Predicted) |
| Flash Point | 368°C |
| Water Solubility | 84.99mg/L(25 ºC) |
| Solubility | Soluble in Ethanol and Methanol |
| Vapor Presure | 1.06E-19mmHg at 25°C |
| Appearance | White to Brown Powder |
| Color | white to tan |
| Merck | 14,9916 |
| pKa | 3.56±0.10(Predicted) |
| Storage Condition | 2-8°C |
| Stability | Hygroscopic |
| Sensitive | Easily absorbing moisture |
| Refractive Index | 1.586 |
| MDL | MFCD00865840 |
| Physical and Chemical Properties | Melting point 116-117°C |
| Use | For the treatment of hypertension |
| In vitro study | Valsartan dose-dependently inhibits angiotensin II-induced vasoconstriction, reducing blood pressure in a renin-dependent model of hypertension. Valsartan is at least as potent as ACE inhibitors, diuretics, beta-blockers and calcium antagonists. |
| In vivo study | Valsartan resulted in improved glucose tolerance, reduced fasting blood glucose levels, and reduced serum insulin levels in Western-style diet mice. Valsartan treatment inhibits Western-style diet-induced increases in serum cytokines interferon gamma and monocyte chemoattractant protein -1. In the islets of mice, Valsartan enhances mitochondrial function and prevents the Western-style diet-induced decrease in glucose-stimulated insulin secretion. In isolated adipocytes, Valsartan blocked or attenuated changes in the expression of several key inflammatory signals caused by the Western diet: interleukin-12 p40, interleukin-12 p35, tumor necrosis factor-alpha, interferon-gamma, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase and AT1R. Valsartan significantly increases insulin-mediated 2-[3H] deoxy-d-glucose (2-[3H],DG) glucose and insulin concentrations and plasma glucose concentrations after ingestion into skeletal muscle and attenuation of glucose load. Valsartan treatment promoted insulin-induced phosphorylation of IRS-1, binding of IRS-1 to the P85 regulatory subunit of phosphoinositide 3-kinase (PI3-k), PI3-K activity, and translocation of GLUT4 to the plasma membrane. Valsartan also reduced tumor necrosis factor-α(TNF-α) expression and hyperoxidation in skeletal muscle of KK-AY mice. |
| Hazard Symbols | Xi - Irritant![]() |
| Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S37/39 - Wear suitable gloves and eye/face protection |
| WGK Germany | 3 |
| RTECS | YV9455000 |
| HS Code | 29339900 |
| Reference Show more | 1. Niu, Guanghao, et al. "Marein ameliorates Ang II/hypoxia‐induced abnormal glucolipid metabolism by modulating the HIF‐1α/PPARα/γ pathway in H9c2 cells." Drug Development Research 82.4 (2021): 523-532.https://doi.org/10.1002/ddr.21770 2. Niu, Guanghao, et al. "Marein ameliorates Ang II/hypoxia‐induced abnormal glucolipid metabolism by modulating the HIF‐1α/PPARα/γ pathway in H9c2 cells." Drug Development Research 82.4 (2021): 523-532.https://doi.org/10.1002/ddr.21770 3. Zhu, Zeng-Yan, et al. "Apigenin-induced HIF-1α inhibitory effect improves abnormal glucolipid metabolism in AngⅡ/hypoxia-stimulated or HIF-1α-overexpressed H9c2 cells." Phytomedicine 62 (2019): 152713.https://doi.org/10.1016/j.phymed.2018.10.010 |